Fate Therapeutics

Update in progress

FATE (NasdaqGM)

Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders globally. Its CAR-NK and CAR-T candidates include FT836 (preclinical for multiple tumors) and FT522 (B-cell lymphoma and autoimmunity). CAR T programs include FT819 (systemic lupus erythematosus), FT839 (complex autoimmune diseases), and FT825 (solid tumors). It collaborates with Ono Pharmaceutical on off-the-shelf, iPSC-derived CAR T cells for solid tumors. Founded 2007, San Diego.